Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?Zacks Investment Research • 06/17/25
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025The Motley Fool • 06/14/25
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single AgentBusiness Wire • 06/13/25
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for DogsBusiness Wire • 06/12/25
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025Business Wire • 06/12/25
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?Zacks Investment Research • 06/11/25
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptSeeking Alpha • 06/10/25
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts sayCNBC • 06/10/25
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZenecaCNBC • 06/09/25
U.S. FDA Approves Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV SeasonBusiness Wire • 06/09/25
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With HyperlipidemiaBusiness Wire • 06/09/25